Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (NCT06211036)

🧪 Interventions in This Study

• Tarlatamab (DRUG)
• Durvalumab (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Participant has provided informed consent prior to initiation of any study specific activities/procedures.
2. Age \>= 18 years (or \>= legal adult age within the country if it is older than 18 years).
3. Completed 3-4 cycles of platinum-etoposide chemotherapy with concurrent durvalumab as first-line treatment of extensive-stage (ES)-SCLC prior to enrollment, without disease progression (ongoing response or stable disease) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1.
5. Minimum life expectancy \> 12 weeks.
6. Toxicities attributed to prior anti-cancer therapy resolved to grade ≤ 1, unless otherwise specified, excluding alopecia or fatigue.
7. Adequate organ function.
8. Histologically or cytologically documented extensive-stage disease (American Joint Committee on Cancer, 2017, IV small-cell lung cancer (SCLC) \[T any, N any, M1 a/b/c\]), or T3 to T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. Participants with prior limited-stage (LS)-SCLC are allowed if the interval is \> 6 months since the end of previous therapy and progression, in discussion with the medical monitor. Exclusion
9. Symptomatic central nervous system (CNS) metastases, or leptomeningeal disease. Participants with treated brain metastases are eligible as per protocol.
10. Prior history of severe or life-threatening events from any immune-mediated therapy.
11. History of other malignancy within the past 2 years, with some exceptions as per protocol.
12. Active or prior documented autoimmune or inflammatory disorders as per protocol.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (219 Sites)

Showing the first 25 of 219 sites.

• Infirmary Cancer Center — Mobile, Alabama
• University of Southern California — Los Angeles, California
• Yale New Haven Hospital — New Haven, Connecticut
• University Cancer and Blood Center LLC — Athens, Georgia
• Emory University — Atlanta, Georgia
• Northeast Georgia Medical Center — Gainesville, Georgia
• University of Illinois Chicago — Chicago, Illinois
• Franciscan Health Indianapolis — Indianapolis, Indiana
• Our Lady of the Lake Cancer Institute — Baton Rouge, Louisiana
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Cancer and Hematology Centers of Western Michigan — Grand Rapids, Michigan
• Mayo Clinic — Rochester, Minnesota
• Allina Health System dba Allina Health Cancer Institute — Saint Paul, Minnesota
• Oncology Hematology Associates — Springfield, Missouri
• Nebraska Cancer Specialists — Omaha, Nebraska
• Astera Cancer Care — East Brunswick, New Jersey
• Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
• Montefiore Medical Center - Bronx — The Bronx, New York
• Duke University — Durham, North Carolina
• Wake Forest University Health Sciences — Winston-Salem, North Carolina
• Oncology Hematology Care Incorporated — Cincinnati, Ohio
• University Hospitals Cleveland Medical Center — Cleveland, Ohio
• The Ohio State University — Columbus, Ohio
• Oncology Associates of Oregon, PC — Eugene, Oregon
• Oregon Health and Science University — Portland, Oregon

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Extensive-Stage Small-Cell Lung Cancer

• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC — Los Angeles, California
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer — Tucson, Arizona
• Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases — Los Angeles, California
• Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) — Springdale, Arkansas
• A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer — Basking Ridge, New Jersey

Explore by condition: All Extensive-Stage Small-Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.